German researchers have developed two novel antibiotics that have shown promise for millions of patients with tuberculosis (TB), leading to lesser side effects than the currently available treatments. 

The drugs, sutezolid, and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to the currently used linezolid, with the potential to replace this current cornerstone in the treatment of drug-resistant TB.

Two international clinical studies on the antibiotics published in two peer-reviewed articles in the journal The Lancet Infectious Diseases showed that both sutezolid and delpazolid are safe, effective, and potential alternatives to linezolid in the treatment of TB.